Display options
Cite
Lee JB, Kim KA, Cho HY, et al. Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer. Sci Rep. 2021;11(1):20263doi: 10.1038/s41598-021-98941-6.
Lee, J. B., Kim, K. A., Cho, H. Y., Kim, D., Kim, W. K., Yong, D., Lee, H., Yoon, S. S., Han, D. H., Han, Y. D., Paik, S., Jang, M., Kim, H. S., & Ahn, J. B. (2021). Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer. Scientific reports, 11(1), 20263. https://doi.org/10.1038/s41598-021-98941-6
Lee, Jii Bum, et al. "Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer." Scientific reports vol. 11,1 (2021): 20263. doi: https://doi.org/10.1038/s41598-021-98941-6
Lee JB, Kim KA, Cho HY, Kim D, Kim WK, Yong D, Lee H, Yoon SS, Han DH, Han YD, Paik S, Jang M, Kim HS, Ahn JB. Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer. Sci Rep. 2021 Oct 12;11(1):20263. doi: 10.1038/s41598-021-98941-6. PMID: 34642332; PMCID: PMC8511250.
Copy Download .nbib Format: NLM
Share it on

Sci Rep. 2021 Oct 12;11(1):20263. doi: 10.1038/s41598-021-98941-6.

Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer.

Scientific reports

Jii Bum Lee, Kyung-A Kim, Ho Yeon Cho, DooA Kim, Won Kyu Kim, Dongeun Yong, Hyukmin Lee, Sang Sun Yoon, Dai Hoon Han, Yoon Dae Han, Soonmyung Paik, Mi Jang, Han Sang Kim, Joong Bae Ahn

Affiliations

  1. Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea.
  2. Graduate School of Medical Science, Brain Korea 21 Project, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea.
  3. Natural Products Research Center, Korea Institute of Science and Technology, Gangnung, Korea.
  4. Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea.
  5. Department of Microbiology and Immunology, Yonsei University College of Medicine, Seoul, Korea.
  6. Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Korea.
  7. Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
  8. Department of Pathology, Yonsei University College of Medicine, Seoul, Korea. [email protected].
  9. Department of Pathology, National Health Insurance Service Ilsan Hospital, Goyang, 10444, Korea. [email protected].
  10. Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea. [email protected].
  11. Graduate School of Medical Science, Brain Korea 21 Project, Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea. [email protected].
  12. Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Korea. [email protected].

PMID: 34642332 PMCID: PMC8511250 DOI: 10.1038/s41598-021-98941-6

Abstract

Recent evidence suggests that Fusobacterium nucleatum (Fn) is associated with the development and progression of colorectal cancer. We aimed to delineate the clinical implications of Fn in metastatic colon cancer. We performed quantitative polymerase chain reaction (qPCR) using DNA samples from synchronous metastatic colon cancer patients with either formalin-fixed paraffin-embedded (FFPE) archival primary site tumor samples or fresh colon tissues. Progression-free survival (PFS)1 and PFS2 were defined as PFS of first- and second-line palliative settings. qPCR for Fn was successfully performed using 112 samples (FFPE, n = 61; fresh tissue, n = 51). Forty-one and 68 patients had right-sided and left-sided colon cancer, respectively. Patients with Fn enriched right-sided colon cancers had shorter PFS1 (9.7 vs. 11.2 months) than the other subgroups (HR 3.54, 95% confidence interval [CI] 1.05-11.99; P = 0.04). Fn positive right-sided colon was also associated with shorter PFS2 (3.7 vs. 6.7 months; HR 2.34, 95% CI 0.69-7.91; P = 0.04). In the univariate analysis, PFS1 was affected by differentiation and Fn positive right-sided colon cancer. The multivariate analysis showed that differentiation (HR 2.68, 95% CI 1.40-5.14, P = 0.01) and Fn positive right-sided colon (HR 0.40, 95% CI 0.18-0.88, P = 0.02) were associated with PFS1. Fn enrichment in right sided colon was not associated with overall survival (OS). Fn enrichment has significantly worse prognosis in terms of PFS1 and PFS2 in patients with right-sided metastatic colon cancers.

© 2021. The Author(s).

References

  1. Cell Host Microbe. 2013 Aug 14;14(2):195-206 - PubMed
  2. Cancer Immunol Res. 2018 Nov;6(11):1327-1336 - PubMed
  3. J Clin Oncol. 2004 Apr 1;22(7):1209-14 - PubMed
  4. J Clin Oncol. 2004 Jan 15;22(2):229-37 - PubMed
  5. Science. 2017 Dec 15;358(6369):1443-1448 - PubMed
  6. Antimicrob Agents Chemother. 2013 May;57(5):2016-25 - PubMed
  7. Science. 2020 May 29;368(6494):973-980 - PubMed
  8. Front Oncol. 2019 May 14;9:396 - PubMed
  9. Cells. 2019 Mar 12;8(3): - PubMed
  10. Int J Cancer. 2015 Sep 15;137(6):1258-68 - PubMed
  11. JAMA Oncol. 2017 Feb 1;3(2):211-219 - PubMed
  12. Genome Res. 2012 Feb;22(2):292-8 - PubMed
  13. CA Cancer J Clin. 2020 May;70(3):145-164 - PubMed
  14. Immunity. 2015 Feb 17;42(2):344-355 - PubMed
  15. Genome Res. 2012 Feb;22(2):299-306 - PubMed
  16. Gut. 2016 Dec;65(12):1973-1980 - PubMed
  17. Ann Surg Oncol. 2018 Jun;25(6):1454-1455 - PubMed
  18. JAMA Oncol. 2015 Aug;1(5):653-61 - PubMed
  19. J Exp Clin Cancer Res. 2019 Jan 10;38(1):14 - PubMed
  20. Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):690-704 - PubMed
  21. Virchows Arch. 2017 Sep;471(3):329-336 - PubMed
  22. Ann Surg Oncol. 2008 Sep;15(9):2388-94 - PubMed
  23. Nat Rev Clin Oncol. 2017 May;14(5):297-315 - PubMed
  24. JCO Glob Oncol. 2020 Mar;6:414-438 - PubMed
  25. Nature. 2012 Jul 18;487(7407):330-7 - PubMed
  26. Ann Surg Oncol. 2018 Oct;25(11):3389-3395 - PubMed
  27. Cell. 2017 Jul 27;170(3):548-563.e16 - PubMed
  28. Oncologist. 2014 Nov;19(11):1156-68 - PubMed
  29. Ann Oncol. 2010 May;21 Suppl 5:v70-7 - PubMed
  30. Clin Transl Gastroenterol. 2016 Nov 3;7(11):e200 - PubMed
  31. Cancer Res. 2014 Mar 1;74(5):1311-8 - PubMed

Publication Types